Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer by Vanderlaan, Paul A et al.
Success and failure rates of
tumor genotyping techniques
in routine pathological samples
with non-small-cell lung cancer
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation VanderLaan, Paul A., Norihiro Yamaguchi, Erik Folch, David H.
Boucher, Michael S. Kent, Sidharta P. Gangadharan, Adnan Majid,
et al. 2014. “Success and Failure Rates of Tumor Genotyping
Techniques in Routine Pathological Samples with Non-Small-
Cell Lung Cancer.” Lung Cancer 84 (1) (April): 39–44. doi:10.1016/
j.lungcan.2014.01.013.
Published Version 10.1016/j.lungcan.2014.01.013
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37034618
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Success and failure rates of tumor genotyping techniques in
routine pathological samples with non-small-cell lung cancer
Paul A. VanderLaan, MD, PhD1,*, Norihiro Yamaguchi, MD, MPH2,*, Erik Folch, MD, MSc1,3,
David H. Boucher, BS2, Michael S. Kent, MD3, Sidharta P. Gangadharan, MD3, Adnan Majid,
MD1,3, Michael A. Goldstein, MD2, Mark S. Huberman, MD2, Olivier N. Kocher, MD, PhD1,
and Daniel B. Costa, MD, PhD2,*
1Department of Pathology; Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, MA
2Department of Medicine; Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, MA
3Department of Surgery; Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, MA
Abstract
Introduction—Identification of some somatic molecular alterations in non-small-cell lung
cancer (NSCLC) has become evidence-based practice. The success and failure rate of using
commercially-available tumor genotyping techniques in routine day-to-day NSCLC pathology
samples is not well described. We sought to evaluate the success and failure rate of EGFR
mutation, KRAS mutation, and ALK FISH in a cohort of lung cancers subjected to routine clinical
tumor genotype.
Methods—Clinicopathologic data, tumor genotype success and failure rates were retrospectively
compiled and analyzed from 381 patient-tumor samples.
Results—From these 381 patients with lung cancer, the mean age was 65 years, 61.2% were
women, 75.9% were white, 27.8% were never smokers, 73.8% had advanced NSCLC and 86.1%
had adenocarcinoma histology. The tumor tissue was obtained from surgical specimens in 48.8%,
core needle biopsies in 17.9%, and as cell blocks from aspirates or fluid in 33.3% of cases.
Anatomic sites for tissue collection included lung (49.3%), lymph nodes (22.3%), pleura (11.8%),
bone (6.0%), brain (6.0%), among others. The overall success rate for EGFR mutation analysis
was 94.2%, for KRAS mutation 91.6% and for ALK FISH 91.6%. The highest failure rates were
observed when the tissue was obtained from image-guided percutaneous transthoracic core-needle
biopsies (31.8%, 27.3%, and 35.3% for EGFR, KRAS, and ALK tests, respectively) and bone
specimens (23.1%, 15.4%, and 23.1%, respectively). In specimens obtained from bone, the failure
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rates were significantly higher for biopsies than resection specimens (40% vs 0%, p=0.024 for
EGFR) and for decalcified compared to non-decalcified samples (60% vs 5.5%, p=0.021 for
EGFR).
Conclusions—Tumor genotype techniques are feasible in most samples, outside small image-
guided percutaneous transthoracic core-needle biopsies and bone samples from core biopsies with
decalcification, and therefore expansion of routine tumor genotype into the care of patients with
NSCLC may not require special tissue acquisition or manipulation.
Keywords
lung cancer; non-small-cell lung cancer; never smokers; epidermal growth factor receptor; EGFR;
anaplastic lymphoma kinase; ALK; KRAS; tumor genotype; failure; bone specimen; core biopsy;
molecular testing
INTRODUCTION
In the United States in 2013, the expected number of new cases of and deaths from lung
cancer will exceed 220,000 and 159,000, respectively (1). The overall, of all stages
combined, five-year survival for the most prevalent form of lung cancer - non-small-cell
lung cancer (NSCLC) - does not exceed 15% despite use of surgical resection, radiotherapy
and systemic chemotherapy (1). The last decade of research in lung cancer has yielded
important advances in the development of targeted therapies that target driver oncogenes (2).
The most prevalent mutated or rearranged oncogenes identified in non-small cell lung
cancers (NSCLCs) are v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS),
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1,
BRAF, ERBB2 and RET (3). Specifically, mutations in EGFR and rearrangements (either
inversions or translocations) involving ALK are part of the pathogenesis of some lung
adenocarcinomas, predominantly in never and/or light smokers, and predict for improved
outcomes with tyrosine kinase inhibitors (TKIs), such as erlotinib and crizotinib,
respectively, that target these aberrant kinases (4–6). As such, molecular testing of lung
cancer specimens has become part of routine clinical practice in the care for patients with
advanced NSCLC.
Currently, the proposed testing guidelines from the College of American Pathologists, the
International Association for the Study of Lung Cancer, the Association for Molecular
Pathology, and the National Comprehensive Cancer Network recommend testing all
advanced NSCLCs with an adenocarcinoma component at the time of diagnosis for EGFR
mutation and for ALK fluorescence in situ hybridization (FISH) analysis (7; 8). These
specimens are more frequently encountered as small biopsy or cytology specimens derived
from either the primary tumor or from lymph node or distant metastatic sites, and processed
as formalin-fixed, paraffin embedded tissue samples.
Limited tumor cellularity in small biopsy or cytology specimens can lead to molecular
testing failure. Additionally, it is recognized that different tissue processing techniques,
including acid decalcification or heavy metal fixatives, can cause DNA degradation and
impede molecular analysis (9). These issues can influence the selection and success rates of
specimens submitted for mutational analysis when considering sampling of bony lesions.
Practically, this can pose a dilemma for the clinician and pathologist alike, in determining
whether an initial biopsy used to establish the diagnosis of NSCLC is sufficient for
additional molecular testing, or whether another specimen must be procured for such a
purpose.
VanderLaan et al. Page 2
Lung Cancer. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
As molecular testing of NSCLCs has become a standard of clinical practice, various
institutions have reported their testing protocol and experience (10–13). From these studies,
one can occasionally glean the failure rates of their specimens, though to our knowledge a
systematic study of genetic testing failure rates for NSCLC using commercially-available
testing in a typical clinical practice setting has not been published to date. Here, we present
the molecular testing efficiency for EGFR, KRAS, and ALK FISH analysis of clinical
specimens from NSCLC patients from our institution over a five year time period, reflecting
real-life clinical practice experience.
MATERIALS AND METHODS
Patient selection
Patients with a diagnosis of lung cancer who were seen by our providers and whose tumors
were genotyped for at least EGFR mutations were identified through an ongoing
Institutional Review Board (IRB) approved protocol at Beth Israel Deaconess Medical
Center (BIDMC2009-P-000182). Patients and tumor pairs were excluded if genotyping was
not performed. There were 381 patient-tumor specimens that were submitted to a
commercial vendor for tumor genotype techniques between 2007 and 2012. The data cut off
for analyses was December 19th, 2012. Study data were collected and managed using
REDCap electronic data capture tools hosted at BIDMC.
Tumor processing and genotype
Surgical (i.e., either incisional or excisional biopsies that required a surgical procedure) and
core needle biopsies were processed using standard techniques: 10% neutral buffered
formalin fixation and paraffin-embedding. For any bone specimens that could not be cut
with a scalpel at the grossing bench,, an acid decalcification was performed using RDO
rapid decalcifier solution (Apex Engineering Products Corporation, Aurora, Illinois)
following formalin fixation. Core needle and small biopsy specimens typically underwent a
brief 15–30 minute decalcification, whereas larger surgical resection specimens were
decalcified for 2–6 hours depending on the amount of calcified bone in the chosen sections.
Cell aspirates or cell concentrates from fluid samples were collected into a methanol-water
fixative (CytoLyt, Hologic Corp., Marlborough, MA) and a single ThinPrep slide prepared,
with residual material used to create a cell block using a plasma-thrombin method prior to
formalin-fixation and paraffin embedding. Once a diagnosis was established on histologic
and/or immunohistiologic staining profiles as per evidence-based recommendations (8), the
residual material in the formalin-fixed paraffin-embedded (FFPE) tissue blocks were
submitted for molecular analysis. When multiple tissue blocks were available, the one with
the highest tumor cellularity was chosen, without additional tumor microdissection or
enrichment. Molecular analysis of tumor specimens was performed by a commercial vendor,
Integrated Oncology (LabCorp, Esoterix Genetic Laboratories, LLC). EGFR mutation
analysis was performed using standard DNA sequencing techniques with exons 18 to 21
sequenced (14; 15). For KRAS mutation analysis, DNA from exon 2 was amplified and
subjected to single nucleotide primer extension to detect mutations at codons 12 and 13.
ALK translocation status was analyzed using the Vysis ALK Break-Apart fluorescence in
situ hybridization (FISH) probe (Abbott Molecular, Inc., Des Plaines, IL), as previously
described (16). Failure of the assays was defined as insufficient/unusable material to isolate
DNA or inability to perform/complete sequencing for EGFR and KRAS mutations, and lack
of hybridization signals after two attempts for ALK FISH.
Data collection
Clinical, pathologic, radiographic and tumor genotyping information was collected from
chart extraction. The site of biopsy (lung, lymph node, pleura, bone, brain, liver,
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pericardium, or adrenal) and the type of biopsy (surgical specimen [both excisional and
incisional], core needle biopsy, or cell block from aspirate/fluid) were extracted from the
medical record. Slides from all specimens that failed molecular testing, as well as a subset of
the successfully genotyped cases were re-reviewed by a pathologist (PAV), with data
compiled on tumor cellularity, use of ancillary studies, histopathologic features, and
specimen processing including decalcification.
Statistical methods
Logistic regression was used for the univariable and multivariable analyses to capture the
influence of each clinical predictive factor on the failure rate of tumor genotyping. The
clinically relevant predictive factors were included into the multivariable analysis regardless
of their statistical significance in the univariable analysis. All categorical variables were
dichotomized in the regression analyses. We report odds ratio (OR) and 95% confidence
interval (95%CI) to each predictive factor. Fisher’s exact test was performed to compare
categorical variables. p-value < 0.05 was considered as statistically significant. All p-values
we reported were two-sided. We performed our statistical analyses with STATA version 12
(STATA Corp, College Station, TX).
RESULTS
Patient and tumor characteristics
Table 1 summarizes the clinical and pathological characteristics of the 381 patient-tumor
pairs that were included in our cohort.
Success and failure rates of tumor genotype techniques
Out of the 381 samples, all were sent for EGFR mutation analysis, 226 for KRAS mutation
analysis, and 275 for ALK FISH (Table 1). In 207 tumors (54.3%), all three tests were
ordered simultaneously. Table 2 details the success and failure rates for EGFR, KRAS, and
ALK analyses techniques. The success rate for EGFR mutation analysis was 94.2% and the
failure rate 5.8%; for KRAS mutation 91.6% and 8.36%, respectively; and for ALK FISH
91.6% and 8.41%, respectively. In the 207 tumors in which the three tests were ordered, the
success rate for EGFR was 92.3%, for KRAS 91.8% and for ALK FISH 89.9% (Table 2). Out
of the 25 failure cases of the latter cohort, 11 failed EGFR, KRAS and ALK concurrently, 4
failed ALK FISH alone, 3 each failed EGFR/ALK or KRAS/ALK pairs, 2 failed KRAS alone,
and 1 EGFR/KRAS or EGFR mutation analysis alone
Tumor characteristics that correlate with increased failure rate
To determine the possible clinical or tumor characteristics that were associated with an
increased incidence of failure of tumor genotyping techniques, we performed both
univariable and multivariable logistic regressions in the 381 samples and focused on EGFR
mutation analysis (due to its higher number of patient-tumor samples). Table 3 indicates the
results. The patient’s sex, ethnicity, smoking history, tumor stage, and histologic subtype
were not associated with an increase in failure of EGFR mutation analysis. However, non-
surgical forms of tumor acquisition (core needle biopsies or cytologic specimens with cell
blocks), with an odds ratio (OR) of 28.45 (p=0.002), and bone as the site of tumor
acquisition, with an OR of 6.16 (p=0.010), were significantly associated with increase
failure rates for EGFR mutational analysis (Table 3). Similarly, non-surgical forms of tumor
acquisition, with an OR of 4.32 (p=0.006), and bone as the site of tumor acquisition, with an
OR of 3.58, p=0.03, were significantly associated with increase failure rates for ALK FISH
analysis (data not shown).
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To better define these tumor characteristics associated with genotype failure, we analyzed
the cohort for differences in success rate by site and type of tissue acquisition (Tables 4 and
5).
Type of tissue acquisition and failure rate of tumor genotype
Out of the 207 patients with concurrent testing, the highest failure rates were observed when
the tissue was obtained from core needle biopsies (30.8%, 20.5%, and 30.8% for EGFR,
KRAS, and ALK tests, respectively) when compared to larger surgical resection specimens
(0%, 4.21%, and 3.16% for EGFR, KRAS and ALK tests, respectively) or cell block
preparations (5.47%, 8.21% and 6.84% for EGFR, KRAS and ALK tests, respectively. In the
latter group, cell block preparations from aspirates or fluid had similar failure rates [data not
shown]).
We further on determined that out of the core needle biopsies, the failure rates were higher
when the tissue of origin was either bone or lung when compared to all other sites (Table 5).
In particular, the failure rate of image-guided percutaneous transthoracic core-needle
biopsies was high at 31.8% for EGFR mutations while the failure rate for bronchoscopy-
guided lung transbronchial biopsies was much lower at 11.1% (Table 5). We compared the
two aforementioned types of lung biopsies in relation to estimated tumor cellularity, tumor
area, use of touch preparation for rapid on-site cytologic evaluation, presence of extensive
desmoplastic stromal response, and number of slides cut from the paraffin block used for
diagnostic immunohistochemical and ancillary studies. The most significant differences
observed in the retrievable specimens were in the use of a touch preparation (image-guided
percutaneous transthoracic core-needle biopsies 17/19 cases versus 0/15 cases for
bronchoscopy-guided lung transbronchial biopsies, p<0.0001) and the number of slides
obtained (image-guided percutaneous transthoracic core-needle biopsies had 9/14 cases with
≥ 10 slides versus 2/12 cases for bronchoscopy-guided lung transbronchial biopsies,
p=0.0214). These findings may infer increased tumor tissue use or loss in image-guided
percutaneous transthoracic core-needle biopsies prior to tumor genotyping.
Bone specimens and failure of tumor genotype
Table 5 shows the success and failure rate by site of tumor acquisition. The highest failure
rates for tumors with more than ten specimens sent for molecular analysis were observed in
samples derived from bone (Tables 4 and 5). The failure rate for EGFR mutation analysis of
tumors obtained from bone was significantly higher than in all other sites combined (4/23
vs. 18/340, p=0.0357). Out of the 207 patients with concurrent testing, the failure rate for
bone-derived specimens was 23.1%, 15.4%, and 23.1% for EGFR, KRAS, and ALK tests,
respectively (data not shown).
We further went on to examine factors that might explain the higher failure rate in
specimens originating from bone. The failure rate was significantly different based on the
type of tissue acquisition, with a higher failure rate from non-surgical biopsy or cytologic
cell block specimens from bone (Table 4). The failure rate was significantly higher in non-
surgical biopsies versus surgical resections for EGFR mutations (40% [4/10] vs. 0% [0/13],
respectively, p=0.024), ALK FISH (44.4% [4/9] vs. 0% [0/9], p= 0.082) and KRAS mutations
(2/9 [22.2%] vs. 0% [0/5], p=0.505).
In addition, decalcification of the tumor tissue prior to preparation of the paraffin sample
correlated with a higher rate of genotype failure. For EGFR mutation analysis, the failure
rate for decalcified versus non-decalcified samples was significantly higher (60% [3/5] vs.
5.5% [1/18], respectively, p=0.021). Representative examples of the histologic features of
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bone-derived specimens that either were successful for or failed subsequent genotyping are
provided in Figure 1.
DISCUSSION
We have shown that our institutional success rate for EGFR, KRAS, and ALK testing of
clinical lung cancer specimens exceeds 90% using routine tissue samples and a commercial
vendor. As molecular testing of non-squamous, non-small cell lung carcinomas has become
the standard of care for patients with advanced stage lung cancer, numerous studies by high-
volume academic centers have been published outlining mutation frequency in different
patient populations (17). Less has been published regarding the actual testing success or
failure of tumor specimens in clinical practice. Overall tumor genotyping success rates
extracted from various studies demonstrate a range from 81–94% following initial
pathologist screen for sufficient tumor cell in the specimen (10; 13; 18; 19). Comparable
results have also been described more specifically for small biopsy and cytology-derived
specimens, with success rates ranging from 83–100% in published studies (12; 20; 21). A
large proportion of these studies perform molecular/FISH testing in-house, whereas here we
describe a large cohort of patient samples with molecular/FISH testing performed by an
independent commercial lab. It is encouraging to find that the overall molecular testing
success rate of 90–94%, as well as the success rate for small biopsy or cytology derived
specimens of 85–88%, demonstrated in this study are right in line with the reported testing
success rates in the literature. Thus, comparable success rates can be achieved in a send-out
manner for institutions or medical centers that either do not have in-house molecular testing
capabilities, or otherwise choose to outsource such tests.
After identifying the overall tumor genotyping success rates; we performed a detailed
analysis using multivariate statistics to identify those factors that might predict testing
failure, and found that while clinical characteristics (patient sex, ethnicity, smoking status,
tumor stage, histologic subtype) had no impact on testing failure, the method of tumor tissue
acquisition and the anatomic site from which that tumor came did correlate with tumor
testing success rates. The finding that smaller biopsy or cytology-derived specimens had a
higher chance of testing failure than surgical specimens is clearly linked to the amount of
tumor cells obtained for analysis: larger specimens generally have ample tissue for
diagnostic workup and testing, whereas the tumor tissue present in small biopsy/cytology
specimens may be largely used for the diagnostic work-up limiting the material available for
subsequent testing. Along these lines, recommendations for limited immunohistochemical
work-up and tissue conservation strategies have been put forth to both maximize the
diagnostic accuracy as well as preserve as much tissue as possible for molecular testing in
these small lung cancer specimens (22).
The majority of tumor genotyping failures from lung specimens were from image-guided
percutaneous transthoracic core-needle biopsies. These biopsies had a high frequency of
rapid on-site cytologic evaluation in the form of touch-imprint cytologic slides prepared
from the core biopsies. This method of cytologic on-site assessment transfers tumor cells
from the tissue core to the cytologic slide, in doing so reduces the number of tumor cells that
remain in the core that is used for diagnosis and molecular testing. Additionally, it was
found that more slides on average were cut from the tissue blocks of image-guided
percutaneous transthoracic core-needle biopsies than other forms of lung biopsies (such as
transbronchial biopsies). More slides cut from the paraffin block mean less material
remaining in the block for subsequent testing. When considering other institution’s
experience, a recent large-scale study for the feasibility of image-guided percutaneous
transthoracic core-needle biopsies for lung tumor genotyping reports slightly lower testing
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failure rates (approximately 20%), though it appears as if cytologic on-site evaluation was
not utilized (20).
Tumor cells obtained from bony metastasis is the other specimen characteristic that was
associated with a higher rate of molecular testing failure. The routine processing of these
specimens incorporating an acid decalcification step so that histologic sections can be cut
poses problems for downstream molecular testing. Acid decalcification of bone tissue
extensively fragments DNA and also interferes with subsequent FISH analysis (9), and
should be avoided if possible for metastatic lung cancer specimens. Even when ample tumor
cellularity is present, acid decalcification often causes subsequent molecular testing failure
(Figure 1A). If the amount of calcified bone tissue is small and the specimen can be cut
without a decalcification step, one greatly increases the chances of successful molecular
testing (Figure 1B). Along these lines, a clinically or radiologically characterized “bone
lesion” can in reality have little or no bone tissue in the biopsy specimen and obviates the
need for tissue decalcification (Figure 1C). Therefore, it is important for pathologists and
clinicians alike to recognize that just because a specimen is labeled as a bone biopsy or a
bony lesion, this should not preclude molecular testing.
From the clinical standpoint, there are many factors that go into deciding what putative
tumor site to biopsy, and how to obtain tissue for diagnosis and ancillary testing. For
patients that initially present with clinically or radiologically apparent stage IV disease, the
principal goal in obtaining a tissue diagnosis should be to both diagnosis and pathologically
stage the patient’s lung cancer simultaneously, using the safest, least invasive, and least
costly test available (23). Although open surgical biopsies are the gold standard for
obtaining ample diagnostic tissue, the associated morbidity/mortality and cost that can be
associated with this modality has motivated the shift towards less invasive small biopsy or
fine needle aspiration of lesions in establishing a pathologic diagnosis of cancer. As has
been shown in this report as well as others, the use of these minimally invasive small biopsy
or cytologic-derived specimens - when adequate tumor cellularity is present and
decalcification has not been performed - are also more than adequate for additional
molecular testing in lung cancer (12; 20; 21).
In conclusion, we have presented a five-year academic institutional experience relating the
feasibility and success rates for lung cancer molecular testing of tissue obtained from a
broad range of specimen types and modes of tissue acquisition. Importantly, since the
molecular testing was not performed in-house, but rather by an independent commercial
vendor, the results and conclusions drawn from this study are broadly applicable to other
institutions or practices that also send out molecular testing of lung cancer specimens.
Attention paid to specific specimen characteristics can help ensure optimal selection of
tumor biopsies for successful genotyping.
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FIGURE 1.
Tumor specimens obtained from bony tissue. A: Failed genotyping of a core needle biopsy
from a glenoid metastasis. Although the specimen demonstrates high tumor cellularity, the
extensive infiltration of bone trabeculae necessitated decacification prior to processing.
Subsequent genotyping from a second specimen (cell block from a transbronchial FNA)
successfully demonstrated a deletion mutation in exon 19 of the EGFR gene. B: Successful
tumor genotyping of a core needle biopsy from a L3 spinal metastasis in a 64 year old
female never smoker. The poorly differentiated adenocarcinoma (5 and 9 o’clock) is seen in
a background of fibrosis with only rare bony trabeculae, thus decalcification was
unnecessary for specimen processing. Compare the appearance of the calcified bone
trabeculae with the decalcified osteoid in part A; the former demonstrates shattering or
fracturing artifact, and had a more basophilic hue. C: Successfully genotyped core needle
biopsy specimen of a sacral metastasis. The poorly differentiated adenocarcinoma can be
seen extending into the periosseous soft tissues (adipose tissue and skeletal muscle on the
right). The lack of calcified tissue in this bony metastasis obviated the need for
decalcification, leading to successful tumor genotyping. All images were taken at 200x
original magnification, hematoxylin and eosin stain.
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Table 1
Baseline characteristics of patients and tumors for which a sample was submitted for somatic genotyping
technologies
All patients(n=381)
Age at the time of biopsy mean(SD) 65.0(11.4)
Women n (%) 233(61.2)
Race n (%)
  White 289(75.9)
  Asian 50(13.1)
  Black 25(6.56)
  Others 17(4.46)
Smoking status n (%)
  Current smoker 66(17.3)
  Former smoker 209(54.9)
  Never smoker 106(27.8)
Stage n (%)
  I 24(6.30)
  II 22(5.77)
  III 47(12.1)
  IV 288(73.8)
Histology n (%)
  Adenocarcinoma 328(86.1)
  Squamous cell carcinoma 11(2.89)
  NSCLC (NOS) 39(10.2)
  Others 3(0.78)
Anatomic site of biopsy n (%)
  Bone 23(6.04)
  Brain 23(6.04)
  Liver 14(3.67)
  Lung 188(49.3)
  Lymph node 85(22.3)
  Pleura 45(11.8)
  Others 3(0.79)
Type of biopsy n (%)
  Core needle biopsy 68(17.9)
  Surgical 186(48.8)
  Cell block from FNA 98(25.7)
  Cell block from fluid 29(7.61)
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All patients(n=381)
EGFR mutation analysis
  Submitted samples n (%) 381(100)
KRAS mutation analysis
  Submitted samples n (%) 226(59.31)
ALK FISH analysis
  Submitted samples n (%) 275(72.17)
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Table 2
Success and failure rates for EGFR mutation, KRAS mutation and ALK FISHtechniques in the submitted
samples
All samples(n=381)
EGFR mutation ALK FISH KRAS mutation
Success n(%)* 359(94.2) 252(91.6) 207(91.6)
  Positive/Mutated 86(22.6) 23(8.36) 71(31.4)
  Negative/Wild-type 273(71.7) 229(83.3) 136(60.2)
Failure n(%)* 22(5.8) 23(8.36) 19(8.41)
Not done n(%)** 0(0) 106(27.8) 155(40.7)
Samples who underwent all tests(n=207)
EGFR mutation ALK FISH KRAS mutation
Success n(%)* 191(92.3) 186(89.9) 190(91.8)
  Positive/Mutated 32(15.5) 11(5.31) 65(31.4)
  Negative/Wild-type 159(76.8) 175(84.5) 125(60.4)
Failure n(%)* 16(7.73) 21(10.1) 17(8.21)
Not done n(%)** 0(0) 0(0) 0(0)
*
Percentage out of the attempted assay
**
Percentage out of the number of all patients
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Table 3
Characteristics of failure cases for EGFR mutation detection and their potential predictive factors by
multivariable logistic regression
Predictive factors No. of patients(%) Multivariable regression
Odds
ratio
95% CI* p value
Male 148(39) 1.00 0.57 to 0.45
Female 233(61) 1.42 3.58
White 289(76) 1.21 0.39 to 0.74
Others 92(24) 1.00 3.64
Non-smokers 106(28) 1.00 0.45 to 0.51
Smokers 275(72) 1.50 5.00
Stage I-III 93(24) 1.11 0.29 to 0.88
Stage IV 288(76) 1.00 4.22
Adenocarcinoma 328(86) 1.00 0.63 to 0.22
Others 53(14) 2.15 7.34
Bone 23(6) 6.17 1.56 to 0.01
Others 358(94) 1.00 24.5
Surgical 186(49) 1.00 3.58 to 0.002
Non-surgical 195(51) 28.5 226.2
95%CI*: 95% Confidence interval.
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